JP3621102B2 - 新規な酵素阻害剤、その合成及び使用方法 - Google Patents

新規な酵素阻害剤、その合成及び使用方法 Download PDF

Info

Publication number
JP3621102B2
JP3621102B2 JP51321195A JP51321195A JP3621102B2 JP 3621102 B2 JP3621102 B2 JP 3621102B2 JP 51321195 A JP51321195 A JP 51321195A JP 51321195 A JP51321195 A JP 51321195A JP 3621102 B2 JP3621102 B2 JP 3621102B2
Authority
JP
Japan
Prior art keywords
compounds
uracil
phenylselenyl
compound according
urdpase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51321195A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09507054A (ja
Inventor
クーニ，マームード エイチ． エル
エヌ．エム． ナーギーブ，ファードス
エフ． シナージ，レイモンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPH09507054A publication Critical patent/JPH09507054A/ja
Application granted granted Critical
Publication of JP3621102B2 publication Critical patent/JP3621102B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP51321195A 1993-11-02 1994-09-30 新規な酵素阻害剤、その合成及び使用方法 Expired - Fee Related JP3621102B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/146,838 1993-11-02
US08/146,838 US5476855A (en) 1993-11-02 1993-11-02 Enzyme inhibitors, their synthesis and methods for use
PCT/US1994/011173 WO1995012400A1 (en) 1993-11-02 1994-09-30 Novel enzyme inhibitors, their synthesis, and methods for use

Publications (2)

Publication Number Publication Date
JPH09507054A JPH09507054A (ja) 1997-07-15
JP3621102B2 true JP3621102B2 (ja) 2005-02-16

Family

ID=22519188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51321195A Expired - Fee Related JP3621102B2 (ja) 1993-11-02 1994-09-30 新規な酵素阻害剤、その合成及び使用方法

Country Status (9)

Country Link
US (3) US5476855A (enExample)
EP (1) EP0725641B1 (enExample)
JP (1) JP3621102B2 (enExample)
AT (1) ATE198046T1 (enExample)
AU (1) AU699914B2 (enExample)
DE (1) DE69426423T2 (enExample)
ES (1) ES2155093T3 (enExample)
PT (1) PT725641E (enExample)
WO (1) WO1995012400A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
EP0748316B1 (en) * 1994-02-28 2002-05-08 Sunkyong Industries Co., Ltd. Pyrimidine acyclonucleoside derivatives
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US6177437B1 (en) * 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
US6608197B2 (en) * 2000-01-25 2003-08-19 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US7501429B2 (en) * 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
CA2448160A1 (en) * 2001-05-25 2002-12-05 Queen's University At Kingston Heterocyclic beta-amino acids and their use as anti-epileptogenic agents
EP1655301B1 (en) * 2003-08-04 2015-03-11 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
CN102441170A (zh) * 2004-12-03 2012-05-09 阿迪赫里克斯技术公司 与5-fu和5-fu前药组合施用dpd抑制剂的方法
US20100158966A1 (en) * 2005-05-24 2010-06-24 Ted Reid Selenium-based biocidal formulations and methods of use thereof
EP1898706B1 (en) * 2005-05-24 2018-04-04 Selenium, Ltd. Selenium-based biocidal formulations and methods of use thereof
US9370187B2 (en) 2005-05-24 2016-06-21 Selenium, Ltd. Selenium-based biocidal formulations and methods of use thereof
US8236337B2 (en) * 2005-05-24 2012-08-07 Selenium, Ltd. Anti-microbial orthodontic compositions and appliances and methods of production and use thereof
US20100158967A1 (en) * 2005-05-24 2010-06-24 Ted Reid Selenium-based biocidal formulations and methods of use thereof
KR101452518B1 (ko) * 2005-08-22 2014-10-21 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
EP2120581A4 (en) * 2007-02-20 2011-03-16 Melior Pharmaceuticals I Inc METHODS OF IDENTIFYING LYN KINASE ACTIVATORS
EP2180894A4 (en) * 2007-07-23 2012-08-29 Melior Pharmaceuticals I Inc METHOD OF ACTIVATING IRS-1 AND ACT
WO2009114325A2 (en) 2008-03-03 2009-09-17 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
EP2488182B1 (en) * 2009-10-14 2017-07-19 Elion Oncology LLC Treating neurotoxicity associated with combinations of 5-FU or its prodrugs and DPD inhibitors
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
EP3609500B1 (en) 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
WO2025260023A1 (en) * 2024-06-14 2025-12-18 Spiral Therapeutics, Inc. Methods of treating otic disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3687931A (en) * 1970-03-19 1972-08-29 Syntex Corp Halogenated purine and pyrimidine nucleosides and process therefor
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
US4868187A (en) * 1980-09-16 1989-09-19 Syntex (U.S.A.) Inc. Anti-viral N-substituted pyrimidines
US4613604A (en) * 1985-07-31 1986-09-23 Brown University Research Foundation Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine
CH676712A5 (enExample) * 1988-03-31 1991-02-28 Mitsubishi Chem Ind
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
DE69126469T2 (de) * 1990-03-29 1998-01-29 Mitsubishi Chem Corp Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
KR0151811B1 (ko) * 1993-12-21 1998-10-15 강박광 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법

Also Published As

Publication number Publication date
EP0725641A4 (enExample) 1996-09-04
US5476855A (en) 1995-12-19
EP0725641A1 (en) 1996-08-14
JPH09507054A (ja) 1997-07-15
AU7847694A (en) 1995-05-23
ES2155093T3 (es) 2001-05-01
WO1995012400A1 (en) 1995-05-11
EP0725641B1 (en) 2000-12-13
DE69426423T2 (de) 2001-07-12
US5721241A (en) 1998-02-24
ATE198046T1 (de) 2000-12-15
AU699914B2 (en) 1998-12-17
USRE37623E1 (en) 2002-04-02
PT725641E (pt) 2001-05-31
DE69426423D1 (de) 2001-01-18

Similar Documents

Publication Publication Date Title
USRE37623E1 (en) Enzyme inhibitors, their synthesis, and methods for use
US5141943A (en) 5-benzyl barbiturate derivatives
CA2167688C (en) Methods and compositions for inhibiting uridine secretion
Tanaka et al. Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio) thymine (HEPT) as potent and selective anti-HIV-1 agents
US9290450B2 (en) Compounds and methods for treating inflammatory and fibrotic disorders
US6911450B1 (en) Pyrimidine acyclonucleoside derivatives, preparation method and use thereof
US20070197462A1 (en) Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
JPS6388185A (ja) 新規な９−デアザグアニン類
JPS6337766B2 (enExample)
EP0290558B1 (en) Antifolate agents
RU2036909C1 (ru) Ацилпроизводные гидроксипиримидинов
CA2176720C (en) Novel enzyme inhibitors, their synthesis, and methods for use
JP2000516578A (ja) アデノシンデアミナーゼ阻害剤
WO2009023495A2 (en) Bisubstrate inhibitors of adenylosuccinate synthetase
JPH06172365A (ja) １０−チアイソアロキサジン誘導体およびその用途
JPS6223723B2 (enExample)
JPH0797324A (ja) 抗ウイルス剤
JPH06199812A (ja) 新規シクロペンテン誘導体
HK1013257B (en) L-2',3'-dideoxy nucleoside analogs as anti-hepatitis b (hbv) and anti-hiv agents
JPH08208612A (ja) ウレア化合物、及びその化合物を有効成分とする抗ヒト免疫不全症ウイルス剤

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040517

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20041019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20041117

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081126

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091126

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091126

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101126

Year of fee payment: 6

LAPS Cancellation because of no payment of annual fees